MIRA INFORM REPORT

 

 

Report No. :

348491

Report Date :

09.11.2015

           

IDENTIFICATION DETAILS

 

Name :

FARMABIOT S.A. DE C.V.

 

 

Registered Office :

Calle 2 L-1 Mz Vi S/N, Toluca De Lerdo, Estado de México 50200

 

 

Country :

Mexico

 

 

Year of Establishment :

1997

 

 

Legal Form :

Sociedad Anónima de Capital Variable

 

 

Line of Business :

Pharmaceutical Manufacturing Industry

 

 

No. of Employee :

50

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

No complaints 

 

 

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

Mexico

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

MEXICO - ECONOMIC OVERVIEW

 

Mexico's $1.3 trillion economy has become increasingly oriented toward manufacturing in the 21 years since the North American Free Trade Agreement (NAFTA) entered into force. Per capita income is roughly one-third that of the US; income distribution remains highly unequal. Mexico has become the United States' second-largest export market and third-largest source of imports. In 2014, two-way trade in goods and services exceeded $550 billion. Mexico has free trade agreements with 46 countries, putting more than 90% of trade under free trade agreements. In 2012, Mexico formally joined the Trans-Pacific Partnership negotiations and formed the Pacific Alliance with Peru, Colombia and Chile. Mexico's current government, led by President Enrique PENA NIETO, emphasized economic reforms during its first two years in office, passing and implementing sweeping education, energy, financial, fiscal and telecommunications reform legislation, among others, with the long-term aim to improve competitiveness and economic growth across the Mexican economy. Although the economy is expected to experience stronger growth in 2015 as a result of increased investment and stronger demand for Mexican exports, growth is predicted to remain below potential for reasons of inefficiencies, with a large portion of the economy and workforce in the informal sector, and corruption. Over the medium-term, the economy is vulnerable to global economic pressures, such as lower external demand, rising interest rates, and low oil prices - approximately 30% of government revenue comes from the state-owned oil company, PEMEX. The increasing integration of supply chains, development of the energy sector, and government-to-government focus on trade facilitation will continue to make the North American region increasingly competitive and contribute to Mexican economic development and strength.

 

Source : CIA

 


 

STATUTORY INFORMATION

 

 

Legal Name:

FARMABIOT S.A. DE C.V.

Trade Name:

FARMABIOT

RFC:

FAR9702117V4

Date Created:

1997

Date Incorporated:

1997

Legal Address:

Calle 2 L-1 Mz Vi S/N
Toluca De Lerdo, Estado de México 50200
México

Operative Address:

Calle 2 L-1 Mz Vi S/N
Toluca De Lerdo, Estado de México 50200
México

Telephone:

52 722 279 0048

Fax:

52 722 279 0048

Legal Form:

Sociedad Anónima de Capital Variable

Email:

abigail.avila@farmabiot.com.mx

Registered in:

Mexico

Website:

www.farmabiot.com.mx

Contact:

Jesús Medina, Director

Staff:

50

Activity:

Pharmaceutical Manufacturing Industry

 

 

BANKS

 

BANAMEX

  

The company does not make its banking data public

 

 

History

 

 The company was founded in 1997

 

 

PRINCIPAL ACTIVITY

 

 

Company dedicated to the commercialization of products for the health care.

Products/Services description:

Pharmaceutical Products

Brands:

ACCOCIT
EMPET
PROBITOR
TAXANIT
RECOPLAT
IRAPLA
ACCOGEM
MOKCELL
NEUKINE
NIMAN
ZODOX

Sales are:

Wholesale

Clients:

Pharmaceutical Industry

Suppliers:

FABTECH TECHNOLOGIES INTERNATIONAL
India

Newtronic Equipment Pvt. Ltd.
India

Operations area:

National

The company imports from

India

The company exports to

No exports

The subject employs

50 employees

Payments:

Regular

 

 

 

 

LOCATION

 

Headquarters :

Calle 2 L-1 Mz Vi S/N
Toluca De Lerdo, Estado de México 50200
México

Branches:

The company does not have branches

Related companies:

Accord Farma, S.A. de C.V
Jaime Balmes No. 11 Piso 3
Ciudad De Mexico, Distrito Federal, 11520 Mexico

 

 

GROUP STRUCTURE AND SUBSIDIARY COMPANIES

 

Listed at the stock exchange:

NA

Capital:

NO

Shareholders:

This is a private company. We could not confirm shareholders.

Management:

Hasmukhbhai Chundgar Nimishbhai, Presidente
Arum Dev Nayyar, Counsel
Sandeep Rajaram Bane, Director 

 

 

 

 

FINANCIAL INFORMATION

 

 This is a private company which does not make its financials public.

USD 2014

 

Revenue

2 100 000

Cash Flow

Normal

 

 

LEGAL FILINGS

 

 

 

 There are no legal connected to the subject

 

 

 

 

SUMMARY

 

 

Company dedicated to the commercialization of products for the health care.

 

It has 17 years of experience in the market with a small-medium sized structure.

 

The company has a sister company and mainly imports from India.

 

There are no negative. 

 

 

RISK INFORMATION

DEBTS

Controlled

PAYMENTS

No Complaint

CASH FLOW

Normal

STATUS

Active

 

 

INTERVIEW

 

NAME

NA 

POSITION

Administrative 

COMMENTS

She confirmed address, related company, staff and activity.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.65.79

UK Pound

1

Rs.99.95

Euro

1

Rs.71.55

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

ASH

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.